757247-99-7

Usage

Uses

Used in Pharmaceutical Industry:
4-Amino-3-Fluoro-2-Chlorobenzonitrile is used as a key intermediate for the synthesis of various drugs, particularly those with anti-cancer and anti-inflammatory properties. Its unique molecular structure allows for the development of medications that can effectively target and treat specific diseases.
Used in Agrochemical Industry:
In the agrochemical sector, 4-Amino-3-Fluoro-2-Chlorobenzonitrile is utilized as an intermediate in the production of pesticides and other agrochemicals. Its incorporation into these products helps enhance their effectiveness in controlling pests and diseases, thereby contributing to increased crop yields and improved agricultural productivity.
Safety Precautions:
Due to its classification as a hazardous material, it is crucial to handle 4-Amino-3-Fluoro-2-Chlorobenzonitrile with care. Adhering to safety guidelines for storage and handling is essential to minimize potential risks and ensure the safe use of this valuable chemical compound in various applications.

InChI:InChI=1/C7H4ClFN2/c8-6-4(3-10)1-2-5(11)7(6)9/h1-2H,11H2

Upstream product

• 115843-99-7 4-bromo-3-chloro-2-fluoroaniline 
• 757247-98-6 4-amino-2-chloro-3-fluoro-benzaldehyde 
• 395-36-8 N-(3-chloro-2-fluorophenyl)acetamide 
• 143360-05-8 N-(4-bromo-3-chloro-2-fluorophenyl)acetamide 

Downstream Products

• 864271-01-2 4-isocyanato-3-fluoro-2-chlorobenzonitrile 
• 1272719-26-2 C₈H₂ClFN₂S 
• 1272718-97-4 4-[7-(3-chloro-4-cyano-2-fluoro-phenyl)-8-oxo-6-thioxo-5,7-diaza-spiro[3.4]oct-5-yl]-2-fluoro-N-methyl-benzamide 
• 1272718-99-6 4-[3-(3-chloro-4-cyano-2-fluoro-phenyl)-5,5-dimethyl-4-oxo-2-thioxo-imidazolidin-1-yl]-2-fluoro-N-methyl-benzamide 
• 1272719-04-6 2-chloro-3-fluoro-4-[3-(4-methanesulfonyl-phenyl)-4,4-dimethyl-5-oxo-2-thioxo-imidazolidin-1-yl]-benzonitrile 
• 1272719-05-7 2-chloro-4-[4,4-dimethyl-3-(6-methyl-pyridin-3-yl)-5-oxo-2-thioxo-imidazolidin-1-yl]-3-fluoro-benzonitrile 
• 1272719-06-8 4-(4,4-dimethyl-5-oxo-2-thioxo-3-p-cyanophenyl-imidazolidin-1-yl)-3-fluoro-2-chloro-benzonitrile 
• 1272719-15-9 2-chloro-4-(4,4-dimethyl-5-oxo-2-thioxo-3-p-tolyl-imidazolidin-1-yl)-3-fluoro-benzonitrile 
• 1272719-17-1 2-chloro-3-fluoro-4-[3-(3-fluoro-4-methyl-phenyl)-4,4-dimethyl-5-oxo-2-thioxo-imidazolidin-1-yl]-benzonitrile 
• 1398045-47-0 C₂₆H₂₆ClFN₄O₂S 
• 1398045-41-4 4-{4-[3-(3-chloro-4-cyano-2-fluoro-phenyl)-5,5-dimethyl-4-oxo-2-thioxo-imidazolidin-1-yl]-phenyl}-2,2,N-trimethyl-butyramide 
• 1398045-33-4 2-chloro-3-fluoro-4-(3-{4-[3-(1H-imidazol-2-yl)-propyl]-phenyl}-4,4-dimethyl-5-oxo-2-thioxo-imidazolidin-1-yl)-benzonitrile 
• 1398045-21-0 4-{4-[3-(3-chloro-4-cyano-2-fiuoro-phenyl)-5,5-dimethyl-4-oxo-2-thioxo-imidazolidin-1-yl]-phenyl}-N,N-dimethyl-butyramide 
• 1398044-95-5 methyl 4-(4-(3-(3-chloro-4-cyano-2-fluorophenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)phenyl)butanoate 

Relevant academic research and scientific papers

ISOQUINOLINE COMPOUNDS AND USES THEREOF

Isoquinoline compounds of formula (I) variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the isoquinoline compounds.

ISOQUINOLINE COMPOUNDS FOR THE TREATMENT OF CANCER

3-Carbonylaminoisoquinoline compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the 3-carbonylaminoisoquinoline compounds.

8-AMINOISOQUINOLINE CompoundS AND USES THEREOF

3-Carbonylamino-8-aminoisoquinoline Compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The Compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the 3-carbonylamino-8-aminoisoquinoline Compounds.

INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE

Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.

INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE

Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, methods for use as Bruton's tyrosine kinase and methods of production.

ISOQUINOLINES AS INHIBITORS OF HPK1

Isoquinoline compounds and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibitng HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the isoquinoline compounds.

ANDROGEN RECEPTOR ANTAGONISTS AND USES THEREOF

Disclosed are substituted thioimidazolidinone compounds and pharmaceutical compositions comprising such compounds. The compounds and compositions can be used for treatment of androgen receptor-associated diseases or disorders, such as prostate cancer, benign prostatic hypertrophy, male hair loss and hypertrichosis.

ANDROGEN RECEPTOR ANTAGONISTS AND USES THEREOF

The present invention relates to novel substituted thioimidazolidinone compounds and pharmaceutical compositions comprising such compounds for treatment of androgen receptor-associated diseases or disorders, such as prostate cancer, benign prostatic hypertrophy, male hair loss, muscle loss, acne and hirsutism.

Cyclic amine compounds

The present invention relates to pharmaceutical agents which are agents for the prophylaxis or treatment of hypogonadism, male climacteric disorder, frailty, cachexia or osteoporosis; the pharmaceutical agents frailty suppressants, muscle strength enhance

Tandem optimization of target activity and elimination of mutagenic potential in a potent series of N-aryl bicyclic hydantoin-based selective androgen receptor modulators

Pharmacokinetic studies in cynomolgus monkeys with a novel prototype selective androgen receptor modulator revealed trace amounts of an aniline fragment released through hydrolytic metabolism. This aniline fragment was determined to be mutagenic in an Ames assay. Subsequent concurrent optimization for target activity and avoidance of mutagenicity led to the identification of a pharmacologically superior clinical candidate without mutagenic potential.